Bioprosthetic Valve Calcification Reduction via Aldehyde Capping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bioprosthetic heart valves undergo calcification due to the inherent properties of glutaraldehyde-fixed tissues, leading to stiffening and degradation, which existing methods fail to adequately mitigate, especially during storage and sterilization processes that involve oxidative damage.
Innovation Solution
A method involving the chemical capping of aldehyde groups in bioprosthetic tissues using agents like ethanolamine and sodium borohydride, followed by dehydration in a glycerol/ethanol solution, to prevent oxidative damage and reduce calcification potential, combined with sterilization using ethylene oxide, gamma irradiation, or electron beam irradiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glutaraldehyde is used to fix bioprosthetic tissue, then the tissue gains structural stability and anti-immunological properties, but the tissue becomes susceptible to calcification due to created calcium binding sites
Solution Approach 1:
The patent introduces capping agents (such as amino compounds, hydroxyl compounds, or carboxyl compounds) as intermediary substances that bind to the aldehyde groups created by glutaraldehyde fixation. These capping agents act as mediators that prevent calcium and phosphate from binding to the tissue, thereby eliminating the harmful calcification effect while preserving the structural stability provided by glutaraldehyde cross-linking.
Solution Approach 2:
The patent removes or neutralizes the harmful aldehyde groups that serve as calcium binding sites through chemical reduction (using reducing agents like sodium borohydride or sodium cyanoborohydride) or capping reactions. This extraction of the harmful functional groups eliminates the calcification pathway while maintaining the beneficial cross-linked structure.
2Stability of the object's composition
If bioprosthetic tissue is dehydrated for storage, then the tissue maintains structural integrity, but oxidative damage increases leading to accelerated calcification
Solution Approach 1:
The patent applies capping agents and reducing agents to the tissue before dehydration and storage. This preliminary chemical treatment caps the aldehyde groups and reduces oxidative susceptibility in advance, so that when the tissue undergoes dehydration and subsequent storage, the harmful oxidative damage and calcification are already prevented at the molecular level.
Solution Approach 2:
The patent creates a chemically inert environment within the tissue matrix by saturating the tissue with capping agents and reducing agents. This inert chemical environment prevents oxidative reactions even when the tissue is dehydrated and stored under conditions that would normally promote oxidation, thereby protecting the tissue during long-term storage.
3Reliability
If sterilization processes are applied to bioprosthetic valves, then the tissue is free from contamination, but oxidative damage and calcification are accelerated
Solution Approach 1:
The patent performs capping and reduction treatments before sterilization processes. By preemptively capping the aldehyde groups and reducing oxidative susceptibility, the tissue is protected against the oxidative damage that would otherwise be caused by sterilization methods such as gamma irradiation, electron beam irradiation, or autoclaving, thereby maintaining sterility without sacrificing tissue integrity.
Solution Approach 2:
The patent provides chemical cushioning by introducing antioxidants and capping agents that absorb or neutralize the oxidative stress generated during sterilization. This beforehand cushioning creates a protective chemical buffer that allows sterilization to proceed effectively while preventing the oxidative damage and subsequent calcification that would normally result.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces calcification and oxidative damage, leading to longer service lifetimes of bioprosthetic materials by blocking calcium and phosphate binding sites and preventing tissue deterioration during storage and implantation.
Implementation Method 1
treating a fully assembled bioprosthetic heart valve including fixed-tissue leaflets in a solution containing an aldehyde capping agent and a reducing agent
Implementation Method 2
treating a fully assembled bioprosthetic heart valve including fixed-tissue leaflets in a solution containing an aldehyde capping agent and a reducing agent
Implementation Method 3
dehydrating the capped tissue with a non-aqueous solution
Implementation Method 4
sterilization using ethylene oxide
Implementation Method 5
sterilization using ethylene oxide, gamma irradiation, or electron beam irradiation
Implementation Method 6
sterilization using ethylene oxide, gamma irradiation, or electron beam irradiation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method for manufacturing a bioprosthetic heart valve comprising treating a bioprosthetic heart valve including fixed-tissue leaflets in a solution containing an aldehyde capping agent.